HRP20010778B1 - Unit dosage form - Google Patents

Unit dosage form

Info

Publication number
HRP20010778B1
HRP20010778B1 HR20010778A HRP20010778A HRP20010778B1 HR P20010778 B1 HRP20010778 B1 HR P20010778B1 HR 20010778 A HR20010778 A HR 20010778A HR P20010778 A HRP20010778 A HR P20010778A HR P20010778 B1 HRP20010778 B1 HR P20010778B1
Authority
HR
Croatia
Prior art keywords
unit dosage
dosage form
relates
present
pharmaceutical
Prior art date
Application number
HR20010778A
Other languages
English (en)
Inventor
William
John
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010778(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of HRP20010778A2 publication Critical patent/HRP20010778A2/hr
Publication of HRP20010778B1 publication Critical patent/HRP20010778B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HR20010778A 1999-04-30 2000-04-26 Unit dosage form HRP20010778B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30
PCT/US2000/011129 WO2000066099A2 (en) 1999-04-30 2000-04-26 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction

Publications (2)

Publication Number Publication Date
HRP20010778A2 HRP20010778A2 (en) 2002-12-31
HRP20010778B1 true HRP20010778B1 (en) 2005-04-30

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20010778A HRP20010778B1 (en) 1999-04-30 2000-04-26 Unit dosage form
HR20000243A HRP20000243A2 (en) 1999-04-30 2000-04-26 Pharmaceutical products

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20000243A HRP20000243A2 (en) 1999-04-30 2000-04-26 Pharmaceutical products

Country Status (47)

Country Link
EP (2) EP1173181B3 (cs)
JP (2) JP2000336043A (cs)
KR (2) KR100577057B1 (cs)
CN (2) CN1292264A (cs)
AT (1) ATE251908T1 (cs)
AU (3) AU3012900A (cs)
BE (1) BE1012957A5 (cs)
BR (2) BR0003046A (cs)
CA (2) CA2307101C (cs)
CH (2) CH692478A5 (cs)
CO (1) CO5170493A1 (cs)
CZ (1) CZ296534B6 (cs)
DE (3) DE20007861U1 (cs)
DK (2) DK200000677A (cs)
DZ (1) DZ3171A1 (cs)
EA (2) EA005416B1 (cs)
ES (2) ES2187234A1 (cs)
FI (1) FI20000976L (cs)
FR (1) FR2795646B1 (cs)
GB (1) GB2351663A (cs)
GR (1) GR1003575B (cs)
HK (1) HK1041204B (cs)
HR (2) HRP20010778B1 (cs)
HU (2) HUP0001632A3 (cs)
ID (1) ID25704A (cs)
IE (1) IE20000315A1 (cs)
IL (3) IL135817A0 (cs)
IT (1) ITMI20000922A1 (cs)
LT (1) LT4758B (cs)
LU (1) LU90569B1 (cs)
LV (1) LV12560B (cs)
MX (2) MXPA00003997A (cs)
NL (1) NL1015027C2 (cs)
NO (2) NO20002097L (cs)
NZ (2) NZ514882A (cs)
PE (1) PE20010071A1 (cs)
PL (2) PL339897A1 (cs)
PT (2) PT1173181E (cs)
SE (1) SE0001518L (cs)
SG (1) SG98384A1 (cs)
SI (2) SI20361A (cs)
SK (1) SK285415B6 (cs)
SV (1) SV2002000055A (cs)
TR (1) TR200001132A3 (cs)
UA (1) UA72248C2 (cs)
WO (1) WO2000066099A2 (cs)
ZA (2) ZA200002058B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL199137B1 (pl) * 1999-08-03 2008-08-29 Lilly Icos Llc Kompozycja farmaceutyczna pochodnej ß-karboliny i jej zastosowanie terapeutyczne
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
WO2001094347A1 (en) * 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
EP1305313A1 (en) 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
MXPA03011080A (es) * 2001-06-05 2004-07-08 Lilly Icos Llc Compuestos tetraciclicos como inhibidores de pde5.
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8580954B2 (en) * 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
WO2019154896A1 (de) * 2018-02-07 2019-08-15 Sapiotec Gmbh Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
EE9800390A (et) 1996-05-10 1999-06-15 Icos Corporation Karboliini derivaadid
BR9810233A (pt) * 1997-04-25 2000-10-17 Pfizer Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
WO2000020033A1 (fr) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
JP2002543128A (ja) * 1999-04-30 2002-12-17 リリー アイコス リミテッド ライアビリティ カンパニー 雌性覚醒障害の処置

Also Published As

Publication number Publication date
FI20000976A0 (fi) 2000-04-26
ZA200108900B (en) 2003-03-26
KR20010020779A (ko) 2001-03-15
JP4975214B2 (ja) 2012-07-11
NO20002097D0 (no) 2000-04-25
HUP0001632A3 (en) 2001-12-28
HUP0200912A3 (en) 2003-07-28
BR0003046A (pt) 2002-07-23
NO322013B3 (no) 2017-11-06
HU0200912D0 (en) 2002-04-29
DE60005940T3 (de) 2015-08-27
EP1415652A2 (en) 2004-05-06
EP1173181B1 (en) 2003-10-15
CO5170493A1 (es) 2002-06-27
CA2307101A1 (en) 2000-10-30
CA2371684A1 (en) 2000-11-09
NZ504163A (en) 2001-11-30
AU4490800A (en) 2000-11-17
FI20000976A7 (fi) 2000-10-30
DK1173181T3 (da) 2004-02-16
SK15632001A3 (sk) 2002-02-05
GR20000100153A (el) 2000-12-29
KR100577057B1 (ko) 2006-05-10
ITMI20000922A0 (it) 2000-04-26
GB2351663A (en) 2001-01-10
LV12560A (en) 2000-11-20
HUP0001632A2 (hu) 2001-05-28
ES2187234A1 (es) 2003-05-16
SE0001518L (sv) 2000-10-31
TR200001132A2 (tr) 2001-01-22
DK1173181T6 (en) 2015-04-27
DE20007861U1 (de) 2000-08-24
SE0001518D0 (sv) 2000-04-26
ES2208317T7 (es) 2015-09-15
DE60005940D1 (de) 2003-11-20
JP2002543116A (ja) 2002-12-17
CA2371684C (en) 2007-10-23
EA200000355A3 (ru) 2001-02-26
SV2002000055A (es) 2002-07-03
EP1173181A2 (en) 2002-01-23
ITMI20000922A1 (it) 2001-10-26
GB0010199D0 (en) 2000-06-14
CA2307101C (en) 2003-01-28
LT4758B (lt) 2001-02-26
UA72248C2 (en) 2005-02-15
IL146098A (en) 2007-06-03
AU2004201988A1 (en) 2004-06-10
ATE251908T1 (de) 2003-11-15
IL146098A0 (en) 2002-07-25
PL339897A1 (en) 2000-11-06
PE20010071A1 (es) 2001-03-22
KR20020008396A (ko) 2002-01-30
LV12560B (en) 2001-04-20
BR0010181A (pt) 2003-02-25
ES2208317T3 (es) 2004-06-16
LT2000035A (lt) 2000-11-27
DZ3171A1 (cs) 2000-11-09
GR1003575B (el) 2001-05-14
PT1173181E (pt) 2004-02-27
CN1384746A (zh) 2002-12-11
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
MXPA01010837A (es) 2002-11-07
FR2795646A1 (fr) 2001-01-05
CN1292264A (zh) 2001-04-25
NO20002097L (no) 2001-10-26
JP2000336043A (ja) 2000-12-05
NL1015027A1 (nl) 2000-10-31
DE60005940T2 (de) 2004-07-29
SK285415B6 (sk) 2007-01-04
NL1015027C2 (nl) 2001-02-14
HUP0200912A2 (en) 2002-08-28
CH1173181H1 (cs) 2019-07-15
MXPA00003997A (es) 2002-03-08
NO20015275D0 (no) 2001-10-29
NO322013B1 (no) 2006-08-07
DE10021266A1 (de) 2000-11-16
IE20000315A1 (en) 2001-03-07
EP1415652A3 (en) 2004-05-12
ZA200002058B (en) 2000-11-02
TR200001132A3 (tr) 2001-01-22
NZ514882A (en) 2003-08-29
SI20361A (sl) 2001-04-30
WO2000066099A2 (en) 2000-11-09
CH692478A5 (de) 2002-07-15
AU769946C (en) 2005-01-13
EA200101008A1 (ru) 2002-04-25
PL197813B1 (pl) 2008-04-30
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
LU90569B1 (fr) 2002-02-27
AU769946B2 (en) 2004-02-12
PT102457A (pt) 2000-11-30
EP1173181B3 (en) 2015-03-25
FI20000976L (fi) 2000-10-30
BE1012957A5 (fr) 2001-06-05
EA200000355A2 (ru) 2000-10-30
WO2000066099A3 (en) 2001-01-18
SI1173181T1 (en) 2004-04-30
PL352629A1 (en) 2003-08-25
SG98384A1 (en) 2003-09-19
NO20015275L (no) 2001-12-06
CN1196487C (zh) 2005-04-13
DK200000677A (da) 2000-10-31
AU3012900A (en) 2000-11-02
CZ20013879A3 (cs) 2002-04-17
ID25704A (id) 2000-11-02
HK1041204B (en) 2004-03-05
FR2795646B1 (fr) 2002-08-16
HRP20000243A2 (en) 2001-12-31
IL135817A0 (en) 2001-05-20
HU230369B1 (hu) 2016-03-29
CZ296534B6 (cs) 2006-04-12

Similar Documents

Publication Publication Date Title
DZ3171A1 (cs)
WO2002000657A3 (en) Condensed pyrazindione derivatives
WO2001080860A3 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: ICOS CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190402

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200426